Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response

Research output: Other contribution (Published)Other contribution

Abstract

Despite advances in neurosurgical techniques and radio- chemotherapy, the treatment of brain tumors remains a challenge. This is particularly true for the most frequent and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival time of GB patients remains only approximately 15 months. The alkylating drug temozolomide (TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and unfolded protein response (UPR). Here, we review these cellular mechanisms and their contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on TMZ chemoresistance in glioma stem cells and GB.
Original languageEnglish (Ireland)
Media of outputReviews
PublisherPERGAMON-ELSEVIER SCIENCE LTD
Volume184
ISBN (Print)0163-7258
ISBN (Electronic)0163-7258
DOIs
Publication statusPublished - 1 Apr 2018

Fingerprint

Dive into the research topics of 'Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response'. Together they form a unique fingerprint.

Cite this